On Jun. 11, 2020, Innovation Pharma and researchers at a U.S. Regional Biocontainment Laboratory (RBL) announced they are…
On May 26, 2020, Innovation Pharma reported receiving data from a leading public health research institute showing Brilacidin…
On May 19, 2020, Innovation Pharma announced that its anti-SARS-CoV-2 (COVID-19) drug candidate, Brilacidin, in an in vitro…
On May 5, 2020, Innovation Pharma reported it had executed executed a Material Transfer Agreement (MTA) with a…
On Apr. 20, 2020, Innovation Pharma reported that based on molecular screening of 11,552 compounds comprising already FDA-approved…
On Apr. 6, 2020, Innovation Pharma announced that it is engaged in discussions with health care provider networks…
On Apr. 1, 2020, Innovation Pharma it had received data supporting Brilacidinﾒs direct inhibition of SARS-CoV-2, the novel…
On Mar. 17, 2020, Innovation Pharma announced details on the Material Transfer Agreement signed with a leading public…
On Mar. 12, 2020, Innovation Pharma announced research procedures that one of the 12 Regional Biocontainment Labs (RBLs)…
On Mar. 10, 2020, Innovation Pharma announced that management was advised that testing of Brilacidin, the Company’s flagship…
On Mar. 9, 2020, Innovation Pharmaceuticals announced it was notified by one of the 12 Regional Biocontainment Labs…
On Mar. 6, 2020, Innovation Pharmaceuticals continues to receive inquiries regarding the potential of Brilacidin, the Company’s novel…
On Mar. 2, 2020, Innovation Pharma provided the scientific rationale and clinical development perspectives for Brilacidin, the Company’s…
On Feb. 27, 2020, Innovation Pharma announced the Company had signed a Material Transfer Agreement (MTA) with one…
On Feb. 24, 2020, Innovation Pharmaannounced the Company submitted a Material Transfer Agreement (MTA) with a leading U.S.-based…
On Feb. 18, 2020, Innovation Pharma announced the Company was exploring its lead defensin mimetic drug candidate, Brilacidin,…